Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Array BioPharma has entered into an oncology pact with Genentech to develop both the companies' small-molecule Checkpoint kinase 1 (ChK-1) program.
Subscribe to our email newsletter
Under the agreement, the companies will develop Genentech’s compound GDC-0425 (RG7602) and Array’s ARRY-575.
The tie up allows Genentech to take care of all clinical development and commercialization activities and to pay a sum of $28m to Array as an upfront payment.
Genentech will also pay clinical and commercial milestones up to $685m and up to double digit royalties on sales of any resulting drugs to Array.
Further financial details are not been disclosed.
Array BioPharma CEO Robert Conway said combining both companies’ programs will maximize their chances for success in developing and commercializing this novel cancer therapy.
"We believe ChK-1 inhibition is a key strategy for enhancing the efficacy of chemotherapeutic and other agents in cancer patients," Conway said.